Tiragolumab functions as an immune checkpoint inhibitor by targeting the T-cell immunoglobulin and ITIM domain (TIGIT). This monoclonal antibody can be utilized either as a monotherapy or in conjunction with Atezolizumab, a PD-L1 inhibitor, to potentially enhance therapeutic efficacy against a variety of solid tumors, with a notable application in the treatment of non-small cell lung cancer (NSCLC). This dual approach may offer a strategic advantage in the modulation of immune responses in oncology settings.
Tiragolumab functions as an immune checkpoint inhibitor by targeting the T-cell immunoglobulin and ITIM domain (TIGIT). This monoclonal antibody can be utilized either as a monotherapy or in conjunction with Atezolizumab, a PD-L1 inhibitor, to potentially enhance therapeutic efficacy against a variety of solid tumors, with a notable application in the treatment of non-small cell lung cancer (NSCLC). This dual approach may offer a strategic advantage in the modulation of immune responses in oncology settings.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
